These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2787471)

  • 21. [Treatment of T-cell lymphoma with immunotherapy of OK-432--a case report (author's transl)].
    Nakayama S; Tsuji K; Kitajima K; Ueno K; Hoshino T
    Rinsho Ketsueki; 1980 Jan; 21(1):66-72. PubMed ID: 6966340
    [No Abstract]   [Full Text] [Related]  

  • 22. [The management of malignant ascites with a streptococcal preparation, OK-432: relation between the clinical effect and auto-tumor cell killing activity by OK-432-induced ascites-derived lymphocytes].
    Katano M; Yamamoto H; Mizoguchi T; Hidaka K; Hisatsugu T; Torisu M
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2464-8. PubMed ID: 3497612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A case of recurrence of gastric cancer with an abdominal wall tumor responding to intratumoral OK-432 administration].
    Saeki T; Kuninobu H; Niimoto M; Hattori T; Ohoya M; Yoshida H; Sata H; Kajitani Y
    Gan No Rinsho; 1987 Apr; 33(4):417-20. PubMed ID: 2952818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The influence of a biological response modifier on thoracic lymphocytes--a study involving clinical cases and animal experiments].
    Hanaue H; Kurosawa T; Miyakawa S; Kitano Y; Nemoto A; Yamoto H; Asagoe T; Shikata J
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1285-9. PubMed ID: 3488025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic effect of OK-432 induced endogenous TNF on tumor bearing mice and cancer patients.
    Watanabe N; Niitsu Y; Yamauchi N; Neda H; Sone H; Urushizaki I; Yamamoto A; Nagamuta M; Sugawara Y
    Immunopharmacol Immunotoxicol; 1988; 10(1):53-65. PubMed ID: 3361071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Augmentation of cytotoxicity of regional lymph node lymphocytes of gastric cancer after intratumoral injection of OK-432].
    Kobayashi G
    Nihon Geka Gakkai Zasshi; 1990 Jan; 91(1):68-76. PubMed ID: 2314383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A case of unresectable advanced gastric cancer with effective treatment by local administration of OK-432 on operation].
    Kodama M; Taniguchi T; Furukawa H; Takahashi T; Hara T
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2301-3. PubMed ID: 2735772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The combined therapy of local administration of OK-432 and radiation in carcinoma of the trachea].
    Mukai M; Morita S; Kawano Y; Tsunemoto H
    Nihon Gan Chiryo Gakkai Shi; 1989 Mar; 24(3):622-5. PubMed ID: 2768974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of biological response modifier on thoracic duct lymphocytes in recurrent gastric cancer. Evaluation of OK-432, a hemolytic streptococcus preparation.
    Hanaue H; Kim DY; Kubota M; Kurosawa T; Shikata J; Kondoh Y; Ogoshi K; Makuuchi H; Nakasaki H; Mitomi T
    Tokai J Exp Clin Med; 1987 May; 12(2):97-102. PubMed ID: 3502432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of urokinase-type plasminogen activator in local immunotherapy.
    Takeda T; Ito Y; Wakasugi E; Kobayashi T; Monden M
    Oncol Rep; 1998; 5(2):329-33. PubMed ID: 9468551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study on enhancement of antitumor immunity in cervical cancer--with reference to administration of immunopotentiators].
    Wakida K
    Nihon Sanka Fujinka Gakkai Zasshi; 1987 Mar; 39(3):432-8. PubMed ID: 3559328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The endoscopic intratumor administration of OK-432 in gastric cancer unsuitable for surgery.
    Nakazawa S; Yoshino J; Kijima Y; Yasumasa N; Ohhashi S; Mizutani K
    Endoscopy; 1989 Jul; 21(4):168-71. PubMed ID: 2776702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunohistological studies of the skin at the injection site of cases receiving the streptococcal agent OK-432].
    Hanaue H; Kurosawa T; Miyakawa S; Horie F; Nemoto A; Yamoto H; Nishimura S; Tsuchiya H; Miura S; Asagoe T
    Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2271-8. PubMed ID: 3879494
    [No Abstract]   [Full Text] [Related]  

  • 34. [Changes in peripheral lymphocyte subsets before and after OK-432 administration in liver cancer].
    Yamamoto S; Omoto K; Yamamoto R; Ideguchi S; Oumi T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):1077-8. PubMed ID: 3963851
    [No Abstract]   [Full Text] [Related]  

  • 35. [Local immunotherapy with streptococcal preparation, OK-432 in superficial bladder tumors, and common antigens between OK-432 and the tumor].
    Fujioka T; Shiraishi M; Tanji S; Koike H; Suzuki K; Kumagai K; Aoki H; Sakuma Y; Ohhori T; Kubo T
    Hinyokika Kiyo; 1989 Feb; 35(2):253-7. PubMed ID: 2735236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combined treatment with radiotherapy and Streptococcus hemolyticus (OK-432) (author's transl)].
    Tsujii H; Mizoe J; Arimoto T
    Nihon Gan Chiryo Gakkai Shi; 1978 Oct; 13(5):560-6. PubMed ID: 722143
    [No Abstract]   [Full Text] [Related]  

  • 37. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
    Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
    J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intratumoral administration of streptococcal preparation (OK-432) to advanced pancreatic cancer.
    Kodama M; Tanaka T
    Hiroshima J Med Sci; 1983 Jun; 32(2):167-71. PubMed ID: 6618899
    [No Abstract]   [Full Text] [Related]  

  • 39. [Clinical and experimental studies on a new intrabronchial infusion therapy of immunopotentiator-OK-432 in lung cancer].
    Gose K; Hirota S; Imajo Y; Adachi S; Yonezawa K; Soejima T; Takada Y; Kimura S; Tsubota N
    Nihon Gan Chiryo Gakkai Shi; 1986 Jul; 21(6):1208-16. PubMed ID: 3782973
    [No Abstract]   [Full Text] [Related]  

  • 40. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
    Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.